Novel Synthetic Lipopeptides as Potential Mucosal Adjuvants Enhanced SARS-CoV-2 rRBD-Induced Immune Response.
SARS-CoV-2 rRBD
lipopeptide
structure-activity relationship
support vector machine
vaccine adjuvant
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2022
2022
Historique:
received:
11
12
2021
accepted:
15
02
2022
entrez:
31
3
2022
pubmed:
1
4
2022
medline:
9
4
2022
Statut:
epublish
Résumé
As TLR2 agonists, several lipopeptides had been proved to be candidate vaccine adjuvants. In our previous study, lipopeptides mimicking N-terminal structures of the bacterial lipoproteins were also able to promote antigen-specific immune response. However, the structure-activity relationship of lipopeptides as TLR2 agonists is still unclear. Here, 23 synthetic lipopeptides with the same lipid moiety but different peptide sequences were synthesized, and their TLR2 activities
Identifiants
pubmed: 35356002
doi: 10.3389/fimmu.2022.833418
pmc: PMC8959576
doi:
Substances chimiques
Adjuvants, Immunologic
0
Adjuvants, Pharmaceutic
0
COVID-19 Vaccines
0
Immunoglobulin G
0
Lipopeptides
0
Toll-Like Receptor 2
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
833418Informations de copyright
Copyright © 2022 Mao, Liu, Liu, Jin, Jin, Xue, Feng, Li, Deng, Cheng, Zou and Li.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Mol Pharm. 2020 Sep 8;17(9):3259-3269
pubmed: 32787271
Front Immunol. 2020 Nov 12;11:599083
pubmed: 33281825
Parasit Vectors. 2016 Feb 20;9:96
pubmed: 26897363
Adv Drug Deliv Rev. 2021 Feb;169:137-151
pubmed: 33340620
J Biochem. 1980 Dec;88(6):1895-8
pubmed: 7462208
J Mol Biol. 1982 May 5;157(1):105-32
pubmed: 7108955
Vaccine. 2011 Sep 2;29(38):6641-9
pubmed: 21742006
Cell Death Dis. 2020 Jan 13;11(1):23
pubmed: 31932577
J Immunother Cancer. 2019 Nov 15;7(1):307
pubmed: 31730025
Biochim Biophys Acta. 2014 Jun;1838(6):1586-93
pubmed: 24480409
Front Immunol. 2020 Oct 02;11:567941
pubmed: 33123139
Vaccine. 2011 Apr 12;29(17):3341-55
pubmed: 20713100
Front Immunol. 2020 Oct 16;11:577823
pubmed: 33178204
Vet Clin North Am Small Anim Pract. 2018 Mar;48(2):231-241
pubmed: 29217317
Eur J Immunol. 2005 Jan;35(1):282-9
pubmed: 15580661
Antiviral Res. 2020 Jun;178:104746
pubmed: 32081741
Methods Mol Biol. 2016;1404:289-298
pubmed: 27076306
Methods Mol Biol. 2017;1494:1-13
pubmed: 27718182
Vaccine. 2013 Sep 13;31(40):4322-9
pubmed: 23880366
Eur J Immunol. 2002 Oct;32(10):2857-65
pubmed: 12355438
Infect Immun. 2004 Mar;72(3):1657-65
pubmed: 14977973
Front Immunol. 2020 Nov 30;11:611337
pubmed: 33329607
Arch Med Res. 2021 Jan;52(1):15-24
pubmed: 32950264
Public Health. 2014 Aug;128(8):686-92
pubmed: 25132389
Nature. 2022 Jan;601(7894):617-622
pubmed: 34814158
Org Biomol Chem. 2020 Jul 15;18(27):5073-5094
pubmed: 32582902
Inflamm Res. 2017 Oct;66(10):843-853
pubmed: 28593434
Vaccine. 2018 Jul 5;36(29):4331-4338
pubmed: 29891349
Nat Commun. 2020 May 20;11(1):2601
pubmed: 32433465
JAMA. 2021 Feb 23;325(8):780-781
pubmed: 33475702
JCI Insight. 2020 May 21;5(10):
pubmed: 32434994
Nat Commun. 2020 Jul 9;11(1):3523
pubmed: 32647131
Front Immunol. 2019 Jun 14;10:1372
pubmed: 31258538
Nat Med. 2013 Dec;19(12):1597-608
pubmed: 24309663
Front Immunol. 2018 Sep 19;9:1963
pubmed: 30283434
Clin Exp Immunol. 2019 May;196(2):189-204
pubmed: 30963549
Adv Exp Med Biol. 2017;1030:185-227
pubmed: 29081055
Immunobiology. 2000 Jan;201(3-4):391-405
pubmed: 10776795
Vaccine. 2021 Apr 15;39(16):2280-2287
pubmed: 33731271
Eur J Immunol. 2002 Aug;32(8):2274-81
pubmed: 12209640
Expert Rev Vaccines. 2011 Apr;10(4):539-50
pubmed: 21506650
Semin Immunol. 2007 Feb;19(1):24-32
pubmed: 17275323